Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dermatologic Toxicities during Multiple Myeloma and Leukemia Therapy
Description
In this session, the speaker discusses dermatologic toxicities associated with therapies for multiple myeloma and acute leukemia. Multiple myeloma, characterized by the proliferation of plasma cells, typically leads to treatments involving drugs like Lenalidomide. While effective, Lenalidomide can cause rashes, impacting patient quality of life. Management approaches include corticosteroids, dose adjustments, and newer therapies like Dupilumab. The speaker presents retrospective data showing Dupilumab can improve tolerance to Lenalidomide in patients with rashes. In addition, the emergence of drugs like Talketamab for multiple myeloma brings new challenges, revealing skin toxicity and a need for dermatological intervention. The treatment landscape also includes IDH inhibitors for acute myeloid leukemia, which can cause dermatologic adverse events, typically with a delayed onset, warranting vigilance from healthcare providers. The discussion further highlights the importance of understanding these toxicities in optimizing patient care and improving their quality of life. Overall, the speaker emphasizes the dermatologist's role in managing skin-related side effects in patients undergoing treatment for hematologic malignancies.
View moreConclusions
- Dermatologic toxicities are common during multiple myeloma and leukemia therapies, with specific treatments like lenalidomide resulting in high rates of rashes in a significant portion of patients.
- Management of lenalidomide-induced rash remains challenging despite traditional approaches like systemic steroids and dose adjustments.
- Dupilumab has been shown to increase tolerability to lenalidomide by effectively treating associated rashes, allowing patients to maintain therapy.
- Talquetamab therapy in multiple myeloma leads to various skin toxicities, necessitating comprehensive management strategies including topical treatments and supportive care.
- Cytokine release syndrome is a major concern post-CAR T therapy, requiring rigorous monitoring and prompt management to address complications effectively.
- Patients receiving IDH inhibitors like gilteritinib commonly experience dermatologic adverse events, with many being severe, although most can continue treatment after proper management.
- There remains an ongoing need for effective interventions and the development of new treatments to improve the quality of life for patients experiencing dermatologic toxicities from therapies.
- Kuo AM, Markova A. Leuk Lymphoma. 2022 Sep;63(9):2233-2237.
- Ann Allergy Asthma Immunol 123 (2019) 394e397.
- Chari A, et al. N Engl J Med. 2022 Dec 15;387(24):2232-2244.
- Inoue S, et al. J Invest Dermatol. 2004 Mar;122(3):565-73.
- Lindsley RC, et al. Blood. 2015 Feb 26;125(9):1367-76.
- Daver, N ., et al. Leukemia 33, 299-312 (2019).
- Paudel A, et al. J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):275-278.
- Stoll JR, Markova A. J Am Acad Dermatol. 2022 Jan;86(1):232-234.
- Bonifant CL, et al. Mol Ther Oncolytics. 2016 Apr 20;3:16011.
- Storgard R, Reingold RE, ..., Markova A. Under Review.